BRCA Gene Mutations and Prostate Cancer
Authors:
- Gvantsa KharaishviliGKGvantsa Kharaishvili
- Mariam KacheishviliMKMariam Kacheishvili
- Giorgi AkhvledianiGAGiorgi Akhvlediani
Open Access
- 18 January 2023
- book chapter
- Published by IntechOpen
Abstract
Prostate cancer remains the second most common cancer in men, with diverse courses from indolent cases to aggressive diseases. Among the key factors implicated in its pathogenesis are genomic alterations such as the TMPRSS2-ERG and related fusion oncogenes, loss of tumor suppressor PTEN, p53 or NKX3.1, inflammation, enhanced DNA damage, and chromosomal instability. Men with prostate cancer who carry BRCA1/2 mutations are at more risk of worse disease and poor prognosis. Cancer cells with mutant BRCA1 or BRCA2 repair genes with defects in homologous recombination are vulnerable to PARP inhibitors that target the genetic phenomenon known as synthetic lethality to exploit faulty DNA repair mechanisms. With relevance to prostate cancer, other features of cancer cells may also sensitize to PARP inhibitors, including aberrant transcription due to the androgen-driven fusion oncogene TMPRSS2-ERG or PTEN loss. Several models of synthetic lethality and potential biomarkers suggested up to date are also discussed. The chapter also highlights the importance of genetic screening of men with BRCA and shows diagnostic utility of plasma-derived circulating tumor DNA.Keywords
This publication has 30 references indexed in Scilit:
- Prostate cancerThe Lancet, 2016
- DNA-Repair Defects and Olaparib in Metastatic Prostate CancerNew England Journal of Medicine, 2015
- Cancer Risks for Men With BRCA1/2 MutationsOncology Nursing Forum, 2013
- Genomic Profiling Defines Subtypes of Prostate Cancer with the Potential for Therapeutic StratificationClinical Cancer Research, 2013
- Addicted to PAR?Cell Cycle, 2012
- Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatmentCell Cycle, 2012
- Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutationsFamilial Cancer, 2011
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandingsMolecular Oncology, 2011
- Original Research: Men's Awareness and Knowledge of Male Breast CancerAJN, American Journal of Nursing, 2010
- Synthetic Lethality — A New Direction in Cancer-Drug DevelopmentNew England Journal of Medicine, 2009